RESUMO
We report a case of a blue-black nodule on the left upper eyelid of a 77-year-old woman. Dermoscopic examination of the lesion revealed a purple or purple-red homogenous opaque area like that often observed in apocrine gland cysts and a yellow-whitish homogenous structure with arborizing vessels. After resection of the tumor, a final diagnosis of collision of an apocrine gland cyst and a trichoblastoma was made. We should note the possibility that trichoblastoma may exhibit a yellow-whitish homogenous structure in dermoscopy.
Assuntos
Glândulas Apócrinas/patologia , Dermoscopia/métodos , Cisto Epidérmico/diagnóstico , Neoplasias Cutâneas/diagnóstico , Neoplasias das Glândulas Sudoríparas/diagnóstico , Idoso , Diagnóstico Diferencial , Pálpebras , Feminino , HumanosAssuntos
Dermoscopia , Ceratose/diagnóstico por imagem , Pele/patologia , Doenças Assintomáticas , Diagnóstico Diferencial , Humanos , Ceratose/patologia , Masculino , Pessoa de Meia-Idade , Pele/diagnóstico por imagem , Neoplasias das Glândulas Sudoríparas/diagnóstico , Parede Torácica , Adenomas Tubulares de Glândulas Sudoríparas/diagnósticoAssuntos
Carcinoma/diagnóstico , Cicatriz Hipertrófica/diagnóstico , Queloide/diagnóstico , Doenças Raras/diagnóstico , Neoplasias das Glândulas Sudoríparas/diagnóstico , Biópsia , Carcinoma/patologia , Carcinoma/cirurgia , Diagnóstico Diferencial , Mãos , Humanos , Imuno-Histoquímica , Masculino , Pessoa de Meia-Idade , Doenças Raras/patologia , Neoplasias das Glândulas Sudoríparas/patologia , Neoplasias das Glândulas Sudoríparas/cirurgia , SiringomaAssuntos
Carcinoma Basocelular/diagnóstico por imagem , Dermoscopia , Neoplasias Primárias Múltiplas/diagnóstico por imagem , Nevo Pigmentado/diagnóstico por imagem , Neoplasias Nasais/diagnóstico por imagem , Neoplasias Cutâneas/diagnóstico por imagem , Biomarcadores Tumorais/metabolismo , Carcinoma Basocelular/patologia , Carcinoma Basocelular/cirurgia , Derme/patologia , Feminino , Humanos , Antígeno MART-1/metabolismo , Pessoa de Meia-Idade , Neoplasias Primárias Múltiplas/patologia , Neoplasias Primárias Múltiplas/cirurgia , Nevo Pigmentado/patologia , Nevo Pigmentado/cirurgia , Neoplasias Nasais/patologia , Neoplasias Nasais/cirurgia , Neoplasias Cutâneas/patologia , Neoplasias Cutâneas/cirurgiaAssuntos
Carcinoma de Apêndice Cutâneo/diagnóstico , Dermoscopia/métodos , Neoplasias Cutâneas/diagnóstico , Neoplasias das Glândulas Sudoríparas/diagnóstico , Biópsia por Agulha , Carcinoma de Apêndice Cutâneo/patologia , Carcinoma de Apêndice Cutâneo/cirurgia , Bochecha/patologia , Diagnóstico Diferencial , Feminino , Humanos , Imuno-Histoquímica , Pessoa de Meia-Idade , Neoplasias Cutâneas/patologia , Neoplasias Cutâneas/cirurgia , Neoplasias das Glândulas Sudoríparas/patologia , Neoplasias das Glândulas Sudoríparas/cirurgia , Resultado do TratamentoRESUMO
BACKGROUND: The removal of unwanted body fat using a noninvasive technique is desirable to patients and physicians. The authors describe a controlled, multicenter, clinical trial assessing the safety and efficacy of a focused therapeutic ultrasound device for noninvasive body contouring. METHODS: Eligible healthy adult subjects were enrolled to the experimental group or the control group at five sites. The experimental group received one treatment with the Contour I device (UltraShape Ltd., Tel Aviv, Israel) in the abdomen, thighs, or flanks and were evaluated over a 12-week period. Efficacy outcomes were reduction of circumference and fat thickness. Circumference reduction was compared with the untreated group and with an untreated area (thigh) within the treated group. Safety monitoring included laboratory testing (including serum lipids), pulse oximetry, and liver ultrasound. RESULTS: One hundred sixty-four subjects participated in the study (137 subjects in the experimental group and 27 in the control, untreated group). A single Contour I treatment was safe and well tolerated and produced a mean reduction of approximately 2 cm in treatment area circumference and approximately 2.9 mm in skin fat thickness. The majority of the effect was achieved within 2 weeks and was sustained at 12 weeks. No clinically significant changes in the measured safety parameters were recorded. Seven adverse events were reported, all of which were anticipated, mild, and resolved within the study period. CONCLUSION: The Contour I device provides a safe and effective noninvasive technology for body contouring.